Retrospective Chart Review to Assess the Relationship Between Depression and Sustained Virological Response From Interferon Treatment for Hepatitis C Virus

2011 ◽  
Vol 33 (10) ◽  
pp. 1400-1405 ◽  
Author(s):  
Robin C. Wackernah ◽  
Mimi Lou ◽  
Susie H. Park
2005 ◽  
Vol 12 (1) ◽  
pp. 51-57 ◽  
Author(s):  
Roberto J. Firpi ◽  
Haizhen Zhu ◽  
Giuseppe Morelli ◽  
Manal F. Abdelmalek ◽  
Consuelo Soldevila-Pico ◽  
...  

Kanzo ◽  
2021 ◽  
Vol 62 (9) ◽  
pp. 578-584
Author(s):  
Yasunao Numata ◽  
Shigeru Sasaki ◽  
Noriyuki Akutsu ◽  
Takehiro Hirano ◽  
Kohei Wagatsuma ◽  
...  

Author(s):  
Anaïs Corma-Gómez ◽  
Juan Macías ◽  
Luis Morano ◽  
Antonio Rivero ◽  
Francisco Téllez ◽  
...  

Abstract Background In the setting of hepatitis C virus (HCV) active infection, liver stiffness (LS)–based strategies identify patients with low risk of developing esophageal variceal bleeding (VB) episodes, in whom unnecessary upper esophagogastroduodenoscopy (UGE) screening can be safely avoided. However, after sustained virological response (SVR), data on the accuracy of the criteria predicting this outcome in HCV-infected patients with cirrhosis, with or without human immunodeficiency virus (HIV) coinfection, are very limited. Methods This was a multicenter prospective cohort study, where HCV-monoinfected patients and HIV/HCV-coinfected individuals were included if they had (1) SVR with direct-acting antiviral–based therapy; (2) LS ≥9.5 kPa previous to treatment; and (3) LS measurement at the SVR time-point ≥14 kPa. Diagnostic accuracy of HEPAVIR, expanded Baveno VI, and HIV cirrhosis criteria, at the time of SVR, was evaluated. Missed VB episodes, negative predictive values (NPVs), and number of spared UGEs were specifically assessed. Results Four hundred thirty-five patients were included, 284 (65%) coinfected with HIV. Seven (1.6%) patients developed a first episode of VB after SVR. In patients without a previous VB episode, HEPAVIR, expanded Baveno VI and HIV cirrhosis criteria achieved NPV for first VB episode after SVR of 99.5% (95% confidence interval [CI], 97.1%–100%), 100% (95% CI 97.8%–100%), and 100% (95% CI 98%–100%) while sparing 45%, 39%, and 44% of UGEs, respectively. When considering HIV coinfection, the performance of the 3 criteria was similar, both in HCV-monoinfected and HIV/HCV-coinfected individuals. Conclusions After SVR, predictive LS-based strategies accurately identify HCV-infected patients, HIV coinfected or not, with low risk of developing VB during follow-up. In these specific patients, using HIV cirrhosis criteria maximize the number of spared UGEs while missing no VB episode.


2012 ◽  
Vol 56 ◽  
pp. S532 ◽  
Author(s):  
S. Manolakopoulos ◽  
H. Kranidioti ◽  
S. Karatapanis ◽  
E. Tsirogianni ◽  
J. Goulis ◽  
...  

2014 ◽  
Vol 28 (7) ◽  
pp. 381-384 ◽  
Author(s):  
Theresa Liu ◽  
Glen T Howell ◽  
Lucy Turner ◽  
Kimberley Corace ◽  
Gary Garber ◽  
...  

BACKGROUND: Marijuana smoking is prevalent among hepatitis C virus-infected patients. The literature assessing the influence of marijuana on liver disease progression and hepatitis C virus antiviral treatment outcomes is conflicting.METHODS: The authors evaluated hepatitis C virus RNA-positive patients followed at The Ottawa Hospital Viral Hepatitis Clinic (Ottawa, Ontario) from 2000 to 2009. Using The Ottawa Hospital Viral Hepatitis Clinic database and charts, information regarding demographics, HIV coinfection, alcohol use, liver biopsy results, treatment outcomes and self-reported marijuana use was extracted. Biopsy characteristics and hepatitis C virus antiviral treatment outcomes were assessed for association with categorized marijuana use by adjusted logistic regression; covariates were specified according to clinical relevance a priori.RESULTS: Information regarding marijuana use was available for 550 patients, 159 (28.9%) of whom were using marijuana at the time of first assessment. Biopsy fibrosis stage and marijuana use data were available for 377 of these 550 (F0-2=72.3%). Overall, marijuana use did not predict fibrosis stage, inflammation grade or steatosis. Sustained virological response and marijuana use data were available for 359 of the 550 cohort participants; a total of 211 (58.8%) achieved a sustained virological response. Marijuana use was not associated with premature interruption of therapy for side effects, the likelihood of completing a full course of therapy or sustained virological response.CONCLUSION: Marijuana use did not influence biopsy histology or alter key hard outcomes of hepatitis C virus antiviral therapy.


Sign in / Sign up

Export Citation Format

Share Document